Multicenter external validation of the radical cystectomy pentafecta in a European cohort of patients undergoing robot-assisted radical cystectomy with intracorporeal urinary diversion for bladder cancer.
Bladder neoplas
Cystectomy
Robotics
Urinary diversion
Urothelial carcinoma
Validation
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
07
03
2021
accepted:
29
05
2021
pubmed:
4
7
2021
medline:
25
2
2022
entrez:
3
7
2021
Statut:
ppublish
Résumé
To perform an external validation of this RC-pentafecta. Between January 2014 and December 2019, 104 consecutive patients who underwent RARC with ICUD within 6 urological centers were analyzed retrospectively. Patients who simultaneously demonstrated negative soft tissue surgical margins (STSMs), a lymph node (LN) yield ≥ 16, absence of major (Clavien-Dindo grade III-V) 90-day postoperative complications, absence of UD-related long-term sequelae, and absence of 12-month clinical recurrence were considered to have achieved RC-pentafecta. A multivariable logistic regression model was used to measure predictors for achieving RC-pentafecta. We analyzed the influence of this RC-pentafecta on survival, and the impact ofthe surgical experience. Since 2014, 104 patients who had completed at least 12 months of follow-up were included. Over a mean follow-up of 18 months, a LN yield ≥ 16, negative STSMs, absence of major complications at 90 days, and absence of UD-related surgical sequelae and clinical recurrence at ≤ 12 months were observed in 56%, 96%, 85%, 81%, and 91% of patients, respectively, resulting in a RC-pentafecta rate of 39.4%. Multivariate analysis showed that age was an independent predictor of pentafecta achievement (odds ratio [OR], 0.96; 95% confidence interval [CI], 0.90. 0.99; p = 0.04). The surgeon experience had an impact on the validation of the criteria. This study confirmed that the RC-pentafecta is reproducible and could be externally used for the outcome assessment after RARC with ICUD. Therefore, the RC-pentafecta could be a useful tool to assess surgical success and its impact on different outcomes.
Identifiants
pubmed: 34216242
doi: 10.1007/s00345-021-03753-y
pii: 10.1007/s00345-021-03753-y
pmc: PMC8602171
doi:
Types de publication
Journal Article
Multicenter Study
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
4335-4344Informations de copyright
© 2021. The Author(s).
Références
J Urol. 2008 Mar;179(3):873-8; discussion 878
pubmed: 18221953
Eur Urol. 2007 Sep;52(3):769-74
pubmed: 17434254
Eur Urol. 2017 Nov;72(5):801-813
pubmed: 28457661
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
J Urol. 2006 May;175(5):1645-9; discussion 1649
pubmed: 16600721
World J Urol. 2009 Aug;27(4):521-6
pubmed: 19145436
BJU Int. 2021 Feb;127(2):182-189
pubmed: 32682331
BJU Int. 2020 Jan;125(1):64-72
pubmed: 31260600
Cancer Epidemiol. 2013 Apr;37(2):99-114
pubmed: 23200731
Cancer. 2008 Jun;112(11):2401-8
pubmed: 18383515
Eur Urol. 2012 Feb;61(2):341-9
pubmed: 22074761
BJU Int. 2016 Feb;117(2):253-9
pubmed: 25307941
J Clin Oncol. 2005 Apr 1;23(10):2358-65
pubmed: 15800327
BJU Int. 2020 Nov;126(5):644-645
pubmed: 32870582
Cancer. 2006 Nov 15;107(10):2368-74
pubmed: 17041887
Curr Opin Urol. 2015 Nov;25(6):570-7
pubmed: 26372035
J Urol. 1980 May;123(5):640-3
pubmed: 7420548
Int J Urol. 2012 Jan;19(1):39-47
pubmed: 22050425
Eur Urol. 2014 Dec;66(6):1065-77
pubmed: 25074764
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
World J Urol. 2015 Dec;33(12):1945-50
pubmed: 25947885
Ann Surg Oncol. 2011 Jul;18(7):2018-25
pubmed: 21246405
Minerva Urol Nefrol. 2019 Dec;71(6):590-596
pubmed: 31619034
Eur Urol. 2019 Apr;75(4):604-611
pubmed: 30337060
Int J Urol. 2013 Apr;20(4):390-7
pubmed: 22970939
Eur Urol. 2017 Mar;71(3):462-475
pubmed: 27375033
J Urol. 1998 Dec;160(6 Pt 1):2015-9; discussion 2020
pubmed: 9817313